---
title: "Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297311060.md"
description: "Medtronic (MDT) reports Q1 earnings on Sept. 1, with analysts forecasting $1.39 EPS and $9.54B revenue. Shares fell 2.2% to $89.97 on Aug. 27. Recent analyst revisions include Needham raising its price target to $114, UBS upgrading to Buy with a $100 target, while TD Cowen and Evercore ISI cut targets to $100 and $105 respectively."
datetime: "2026-08-28T10:03:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297311060.md)
  - [en](https://longbridge.com/en/news/297311060.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297311060.md)
generator: "portal-rs"
---

# Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

**Medtronic plc** (NYSE:MDT) will release its first earnings report before the opening bell on Tuesday, Sept. 1.

Analysts expect the Galway, Ireland-based company to report quarterly earnings of $1.39 per share, up from $1.26 per share in the year-ago period. The consensus estimate for Medtronic’s quarterly revenue is $9.54 billion. It reported $8.54 billion last year, according to Benzinga Pro.

On Aug. 20, the company’s board of directors declared a cash dividend for the second quarter of 72 cents per ordinary share.

Medtronic shares fell 2.2% to close at $89.97 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

-   Needham analyst Mike Matson maintained a Buy rating and boosted the price target from $101 to $114 on Aug. 27, 2026. This analyst has an accuracy rate of 58%.
-   BTIG analyst Ryan Zimmerman maintained a Buy rating with a price target of $91 on Aug. 18, 2026. This analyst has an accuracy rate of 65%.
-   UBS analyst Priya Sachdeva upgraded the stock from Neutral to Buy and raised the price target from $85 to $100 on July 28, 2026. This analyst has an accuracy rate of 67%.
-   TD Cowen analyst Joshua Jennings maintained a Buy rating and cut the price target from $119 to $100 on July 10, 2026. This analyst has an accuracy rate of 57%.
-   Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating and cut the price target from $106 to $105 on July 6, 2026. This analyst has an accuracy rate of 64%.

Considering buying MDT stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)

## Related News & Research

- [MDT Partners with OnTrac AI to Help Credit Unions Build AI Readiness and Take Action](https://longbridge.com/en/news/296794229.md)
- [How Investors Are Reacting To Medtronic (MDT) Cardiac Ablation Surge And Near-Dividend-King Milestone](https://longbridge.com/en/news/296452586.md)
- [Medtronic announces cash dividend for second quarter of fiscal year 2027 | MDT Stock News](https://longbridge.com/en/news/296535532.md)
- [Hubbell Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/297191681.md)
- [Perma-Pipe International - Enters 2026 Credit Agreement With JPMorgan Chase Bank On August 25, 2026 - SEC Filing](https://longbridge.com/en/news/297184704.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**